Elizabeth Guerrero-Berroa1,2, Ramit Ravona-Springer3,4, Anthony Heymann4,5, James Schmeidler1, Hadas Hoffman5, Rachel Preiss5, Keren Koifmann3, Lior Greenbaum3, Andrew Levy6, Jeremy M Silverman1,2, Derek Leroith7, Mary Sano1,2, Michal Schnaider-Beeri1,3. 1. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. 2. James J. Peters Veterans Affairs Medical Center, Bronx, NY, 10468, USA. 3. The Joseph Sagol Neuroscience Center, Sheba Medical Center, Ramat Gan, Israel. 4. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 5. Maccabi Healthcare Services, Tel Aviv, Israel. 6. Technion Faculty of Medicine, Technion Israel Institute of Technology, Technion, Haifa, Israel. 7. Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Abstract
OBJECTIVE: The haptoglobin (Hp) genotype has been associated with cognitive function in type 2 diabetes. Because ethnicity/culture has been associated with both cognitive function and Hp genotype frequencies, we examined whether it modulates the association of Hp with cognitive function. METHODS: This cross-sectional study evaluated 787 cognitively normal older individuals (>65 years of age) with type 2 diabetes participating in the Israel Diabetes and Cognitive Decline study. Interactions in two-way analyses of covariance compared Group (Non-Ashkenazi versus Ashkenazi Jews) on the associations of Hp phenotype (Hp 1-1 versus non- Hp 1-1) with five cognitive outcome measures. The primary control variables were age, gender, and education. RESULTS: Compared with Ashkenazi Jews, non-Ashkenazi Jews with the Hp 1-1 phenotype had significantly poorer cognitive function than non-Hp 1-1 in the domains of Attention/Working Memory (p = 0.035) and Executive Function (p = 0.023), but not in Language/Semantic Categorization (p = 0.432), Episodic Memory (p = 0.268), or Overall Cognition (p = 0.082). After controlling for additional covariates (type 2 diabetes-related characteristics, cardiovascular risk factors, Mini-mental State Examination, and extent of depressive symptoms), Attention/Working Memory (p = 0.038) and Executive Function (p = 0.013) remained significant. CONCLUSIONS: Older individuals from specific ethnic/cultural backgrounds with the Hp 1-1 phenotype may benefit more from treatment targeted at decreasing or halting the detrimental effects of Hp 1-1 on the brain. Future studies should examine differential associations of Hp 1-1 and cognitive impairment, especially for groups with high prevalence of both, such as African-Americans and Hispanics.
OBJECTIVE: The haptoglobin (Hp) genotype has been associated with cognitive function in type 2 diabetes. Because ethnicity/culture has been associated with both cognitive function and Hp genotype frequencies, we examined whether it modulates the association of Hp with cognitive function. METHODS: This cross-sectional study evaluated 787 cognitively normal older individuals (>65 years of age) with type 2 diabetes participating in the Israel Diabetes and Cognitive Decline study. Interactions in two-way analyses of covariance compared Group (Non-Ashkenazi versus Ashkenazi Jews) on the associations of Hp phenotype (Hp 1-1 versus non- Hp 1-1) with five cognitive outcome measures. The primary control variables were age, gender, and education. RESULTS: Compared with Ashkenazi Jews, non-Ashkenazi Jews with the Hp 1-1 phenotype had significantly poorer cognitive function than non-Hp 1-1 in the domains of Attention/Working Memory (p = 0.035) and Executive Function (p = 0.023), but not in Language/Semantic Categorization (p = 0.432), Episodic Memory (p = 0.268), or Overall Cognition (p = 0.082). After controlling for additional covariates (type 2 diabetes-related characteristics, cardiovascular risk factors, Mini-mental State Examination, and extent of depressive symptoms), Attention/Working Memory (p = 0.038) and Executive Function (p = 0.013) remained significant. CONCLUSIONS: Older individuals from specific ethnic/cultural backgrounds with the Hp 1-1 phenotype may benefit more from treatment targeted at decreasing or halting the detrimental effects of Hp 1-1 on the brain. Future studies should examine differential associations of Hp 1-1 and cognitive impairment, especially for groups with high prevalence of both, such as African-Americans and Hispanics.
Authors: Peter T Nelson; Charles D Smith; Erin A Abner; Frederick A Schmitt; Stephen W Scheff; Gregory J Davis; Jeffrey N Keller; Gregory A Jicha; Daron Davis; Wang Wang-Xia; Adria Hartman; Douglas G Katz; William R Markesbery Journal: Biochim Biophys Acta Date: 2008-08-22
Authors: Rob P W Rouhl; Annelien E C S Mertens; Robert J van Oostenbrugge; Jan G M C Damoiseaux; Lucienne L Debrus-Palmans; Léon H G Henskens; Abraham A Kroon; Peter W de Leeuw; Jan Lodder; Jan Willem Cohen Tervaert Journal: Stroke Date: 2011-10-06 Impact factor: 7.914
Authors: Andrew P Levy; Irit Hochberg; Kathleen Jablonski; Helaine E Resnick; Elisa T Lee; Lyle Best; Barbara V Howard Journal: J Am Coll Cardiol Date: 2002-12-04 Impact factor: 24.094
Authors: P Godeau; C Frances-Michel; J Wechsler; P Weinbreck; B Wechsler; G Herreman; Y Pinaudeau Journal: Rev Med Interne Date: 1981 Impact factor: 0.728
Authors: Rebecca K West; Ramit Ravona-Springer; James Schmeidler; Derek Leroith; Keren Koifman; Elizabeth Guerrero-Berroa; Rachel Preiss; Hadas Hoffman; Jeremy M Silverman; Anthony Heymann; Michal Schnaider-Beeri Journal: Am J Geriatr Psychiatry Date: 2014-01-23 Impact factor: 4.105